


PHREEDOM (Phase 3) | A 52-week, randomized, placebo-controlled, open-label, phase 3 trial of tenapanor for hyperphosphatemia

564 PATIENTS WITH HYPERPHOSPHATEMIA RECEIVING MAINTENANCE DIALYSIS

Baseline characteristics during the RTP




Average age **58 years**

Average time since first dialysis: **56 months**

Patients receiving **hemodialysis and peritoneal dialysis** were included

PRIMARY ENDPOINT

Difference in the change in serum P between tenapanor and placebo from the beginning to end of the RWP in the efficacy analysis set.



SAFETY AND TOLERABILITY

Patients reporting diarrhea during the RTP (tenapanor vs sevelamer carbonate):

222/419 (53%)



10/137 (7%)



Serious adverse events during the RTP (tenapanor vs sevelamer carbonate):


73/419 (17%)



32/137 (23%)




TRIAL DESIGN



SECONDARY ENDPOINT: CHANGE IN SERUM P OVER THE RTP



In the **ITT POPULATION**, mean serum P decreased from **7.4 mg/dL** at period-specific baseline to **5.9 mg/dL** at week 26, with a mean (SD) decrease of **1.4 (1.8) mg/dL**



STUDY LIMITATIONS

- Conclusions drawn from the responder analysis have limited generalizability
- These results should be interpreted with caution as this part of the trial was open label with no placebo control

Reprinted with permission from Block GA et al. *Kidney 360*. 2021. Copyright © 2021 by the American Society of Nephrology.

bid, twice a day; ITT, intent-to-treat; P, phosphate; RTP, randomized treatment period; RWP, randomized withdrawal period.

NCT03427125. Block GA et al. *Kidney 360*. 2021;2:1600-10.

MED-US--2300033